Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (January 2018)

38 slides from Windtree Therapeutics's investor presentation, Jan 8, 2018

  1. Slide 1: Corporate Presentation January 2018

    Sv we WINDTREE Corporate Presentation January 2018 OTCQB:WINTD

  2. Slide 2: Forward-looking Statement

    Forward-looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreem

  3. Slide 3: Windtree Therapeutics

    Windtree Therapeutics = Public, small cap biopharmaceutical / medical device company = Based in Warrington, PA with approximately 27 employees = Focused in the acute respiratory area with a lead program expected to address a significant need and expand the Respiratory Distress Syndrome (RDS) in prem

  4. Slide 4: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Primary characteristic is surfactant deficiency in underdeveloped lungs of premature infants (born with a lack of natural lung surfactant required for open airways and proper gas exchange — O, in and CO, out) American Academy of Pediatrics guidelines recommend pro

  5. Slide 5: Current RDS Treatment Pathways

    Current RDS Treatment Pathways Initial treatment options include _— * invasive and non-invasive methods: Surfactant Invasive mechanical NCPAP Support until presumptive Therapy + ventilation (IMV) endogenous surfactant production f fy a * Animal-derived surfactant * Requires sustained * Non-invasive

  6. Slide 6: Clinicians Seeking a NonInvasive Way to Deliver Surfactant

    Clinicians Seeking a NonInvasive Way to Deliver Surfactant What is wanted: Y¥ Avoid the risks and complications associated with delivery of surfactant therapy via intubation and mechanical ventilation Y Possibility of repeat doses Y Avoid clinical instability associated with administration of liquid

  7. Slide 7: Windtree Technology Platform - AEROSURF

    Windtree Technology Platform - AEROSURF® Potential to Provide Both Non-Invasive and Invasive Solutions to Treat RDS Proprietary Synthetic KL4 Surfactant Designed to be structurally similar to human lung surfactant Liquid KLa surfactant (intratracheal instillate) for RDS approved by the FDA Lyophiliz

  8. Slide 8: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® RISKS Surfactant Therapy Reysrsing surfactant deficientyhas ‘a profound positive impact on respiration Surfactant therapy delivers near-immediate clinical improvement BPD Infection, ventilator-induced pneumonia Pain, discomfor Lofig-term impacts including\vocal

  9. Slide 9: Potential Drivers of AEROSURF Opportunity

    Potential Drivers of AEROSURF® Opportunity #1 20-30% fPrice Market stated unmet reduction in (but § Total Expansion needinRDS —nCPAP failure is Hospital Cost) P meaningful “Noninvasive Results in >40% Potential for Potential to bring surfactant delivery” reported, positive health surfactant therapy

  10. Slide 10: Significant RDS Global Revenue Opportunity

    Significant RDS Global Revenue Opportunity 8 to 10 Million Low Birth Weight Children Born Every Year Globally Estimated 2016 Annual Revenue * Only 50% to 60% of RDS patients currently treated with surfactant therapy Invasive surfactant therapy only’ us $90 million * Opportunity to expand $800MM - tr

  11. Slide 11: Medical Device and Device Studies

    Medical Device and Device Studies

  12. Slide 12: Innovative Aerosol Delivery System (ADS)

    tary Innovative Aerosol Delivery System (ADS) Designed specifically to aerosolize and deliver KLa surfactant * AEROSURF® innovation made possible by novel medical device * Unique aerosol delivery system (ADS) technology utilizing pressure and heated capillary has demonstrated ability to break throug

  13. Slide 13: ADS Technology Provides Better Output Rate

    ADS Technology Provides Better Output Rate Aerosolizes surfactant as well as saline Aerosol output rate Output with Saline (mL/minute) Output with KL, Surfactant (30mg TPL/mL) 120 220 12 2 ¥ 08 a i > & z 0.4 =e 2 a Ae g ea * Ooo sé pee oe; oe, £ « Saline output of ADS technology is close to KL, surf

  14. Slide 14: Lung Deposition Study in Non-Human Primates

    WO eezeeunics Lung Deposition Study in Non-Human Primates * Use of non-human primates (cynomolgus macaques) - Nose, throat, & lung anatomy comparable to infants; respiratory function similar to preterm infants * Radiolabeled KL4 surfactant aerosolized using Aerosol Delivery System (ADS), delivered v

  15. Slide 15: AEROSURF Clinical Studies

    AEROSURF” Clinical Studies GS winvtREE Py

  16. Slide 16: AEROSURF Phase Program Components

    ER AEROSURF” Phase 2 Program Components Study / Activity Rationale / Objective pst | Phase 2a 2a Expansion Phase 2a Phase 2b Other Studies: Observational Study Lung Deposition Study Other Activities: Licensing in Asia Device Development FDA Interaction Initial safety & tolerability (29-34 wk gestati

  17. Slide 17: nCPAP Failure Through Hours by Dose Group

    45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours Time to nCPAP Failure Time Until any Intubation - Dosing Group 3&4 ata: 0106/2016 100% oof eal ~' L 80% + 60% 21/40 40%, ‘Subjects Not Intubated (%) Percent Subjects Failed 20% r T T 0% ° 2 ™ 6 © CPAP Only 75 & 100 mey/| (45.860 min) ‘Tre

  18. Slide 18: AEROSURF Safety and Tolerability Assessment

    AEROSURF® Safety and Tolerability Assessment = The FDA requested that we conduct a separate safety study in smaller premature infants before including them in blinded studies Multicenter, randomized, open-label, controlled study in 48 premature infants 26 to 28 weeks GA receiving nCPAP for RDS to ev

  19. Slide 19: Observation Related to Bronchopulmonary Dysplasia (BPD)

    AEROSURF® Potentially Important Observation Related to Bronchopulmonary Dysplasia (BPD) BPD Rate Patients AEROSURF 0% 0/24 Control 25% 6/24 Bronchopulmonary Dysplasia (BPD) or chronic lung disease of the newborn is one of the most common complications of prematurity and RDS treatments. It occurs in

  20. Slide 20: AEROSURF Phase 2b Study

    AEROSURF” Phase 2b Study (28 to 32 wk GA) Trial Objectives Trial Design 221 Patients Enrolled * Evaluate safety and * 3 dose groups: ili North tolerability 25 minute, 40mg/kg pen (up to 2 repeat doses) 34% * Demonstrate efficacy ¥50 minute, 80m¢/kg * Determine effect size (up to 2 repeat doses) for

  21. Slide 21: AEROSURF Phase 2b Incidence of nCPAP Failure

    AEROSURF® Phase 2b Incidence of nCPAP Failure Preplanned mITT Without Treatment Interruptions Demonstrates Targeted Reduction * All Sites 45% aa 4 27% 40% relative reduction 35% + 32% 30% 25% 20% CPAP Only 40 mg/kg 80 mg/kg (N=71) (25 min) (50 min) (N=64) (N=44) 60% 50% +} 40% 30% 20% + 10% + 0% | U

  22. Slide 22: Potential for Reduced Respiratory Support

    AEROSURF® - Potential for Reduced Respiratory Support in Patients Who Failed nCPAP When on AEROSURF 140 120 100 20 60 40 20 ° 80me/ke, AcPAP Only 8Ome/ke ‘CPAP Only (n=27) (n=23) (n=29) (n=26) Hours Mechanical Ventilation Supplemental Oxygen, In patients who failed nCPAP and required intubation and

  23. Slide 23: Safety & Tolerability Profile

    - Safety & Tolerability Profile Similar for Treatment and Control Populations = The adverse event and serious adverse event profile was similar across the 3 groups = Complications of prematurity were also similar 40 mg/kg 80 mg/kg | nCPAP Only (25 min) (50 min) Acquired Sepsis 12 ( 18%) 13 ( 20%) 16

  24. Slide 24: Summary of Efficacy Signals in the Phase 2 Program

    Summary of Efficacy Signals in the Phase 2 Program Post-hoc pooled analysis of Phase 2 failure rates. 28% = Post-hoc pooled analysis of patients inthe —s« mud relative phase 2 program (3 studies) treated in 40% 36% ee doses > 45 minutes dosed as intended 30% (uninterrupted) shows a notable reduction

  25. Slide 25: Evolution of Aerosolized Delivery System from Phase 2 to Phase 3

    Si @ Evolution of Aerosolized Delivery System (ADS) from Phase 2 to the Next Generation, Phase 3 / “Go to Market” Device Phase 2 Phase 3 / Commercial icons — palaces eae o. sve sor ater omer pon Le acu merge ty “2012 ~ 2017 + 2018 and beyond * Developed in conjunction with Battelle s Daveloping ineo

  26. Slide 26: Complete Device Development and Transition to Next Generation ADS

    Complete Device Development and Transition to Next Generation ADS in 2Q 2018 Next Generation ADS Features Addressing Filter Clogging = Designed to utilize the same aerosol = Filter diameter doubled delivery technology to match © Surface cross section| important aerosol characteristics of increased b

  27. Slide 27: AEROSURF Clinical Development Next Steps for 2018

    AEROSURF® Clinical Development Next Steps for 2018 Generate the strongest possible position and transition to phase 3 Execute a Bridge Study to transition the new, Next Gen device in order to meet the following objectives: 1. Demonstrate adequate, consistent performance for the new Next Gen device —

  28. Slide 28: AEROSURF Bridge Study

    AEROSURF® Bridge Study Blinded study; nCPAP alone as Dose: 50 min. with up to 4 repeat doses; control versus adding minimum 20 minute wait between doses AEROSURF® treatment * Ph2b was 50 min. high dose, 2 repeats possible with a 2 hour wait between = GA range: 26-32 weeks doses * N=70 planned (35 pe

  29. Slide 29: Program Evolution and Changes Intended to Increase Probability of Success

    Program Evolution and Changes Intended to Increase the Probability of Technical Success and Continue to Strengthened Data = We have reproduced positive results in our Phase 2a and Phase 2b and have learning’s to apply in trial design and execution = Utilize the Next Gen ADS which is designed to miti

  30. Slide 30: Other Potential Development Activities

    Other Potential Development Activities - Lyophilized Lucinactant (LS) - Preclinical Activities GS winvtREE

  31. Slide 31: Lyophilized Lucinactant

    Lyophilized Lucinactant A Second Asset Can Expand the Opportunity Lyophilized Lucinactant LS Characteristics Lyophilized dosage form of our KL4 surfactant drug product that was previously approved by the FDA asa liquid dosage form Currently used in AEROSURF® development program Improvements and bene

  32. Slide 32: Leverage Technology to Advance Acute Pulmonary Disease Care Beyond RDS

    Leverage our Innovative Technology to Advance Acute Pulmonary Disease Care and Outcomes Beyond RDS as = Program Focus HPhase2 Potential Application ALI - Radiation Preclinical (7 studies) Prevention of acute & AG anes Lung chronic changes (fibrotic) EEO Nee aE Ey; a Mitigate lung injury, ‘SARS, H1N1

  33. Slide 33: Platform Exclusivities

    Platform Exclusivities Broad Multi-Faceted Exclusivity Portfolio Regulatory Exclusivities * Orphan Drug Designation in RDS for the U.S. and EU FDA Patents = Lyophilized KL4 Surfactant Portfolio - to 2033 eae = Aerosol Delivery System Portfolio - through 2031+ Trade Secrets/Know-How = Methods of Manu

  34. Slide 34: 2017 Accomplishments

    17 - A Productiv 2a Study in 26-28 wk GA Regulatory GS winvtREE BO tree 2017 Accomplishments

  35. Slide 35: 2018 Objectives

    2018 Objectives Complete Device Development delivering an extremely consistent, high performing Phase 3 / “go to market” drug delivery platform C=) Solid execution in the clinic with the FDA ro Bridge Study AEROSURF and Lyo Lucinactant LS Global Regulatory Clarity and employed in development 2 Succe

  36. Slide 36: AEROSURF Development and Deliverables Overview

    AEROSURF® Development and Deliverables Overview 2018 a @ | @ I e i a Le] oun: Staines J Device Clinical Clinical Start Up Activities EU=Scientific Advice \ EU--Ped. Investigation Plan (PIP) j Regulatory . A, J FDA= Ped. study Plan (PSP) FDA=L5 Advice Medical Devi Review 112018 2.2018 / Mid-2019 v Ne

  37. Slide 37: Value Creating Potential

    se B Value Creating Potential ) 56 WINDTREE THERAPEUTICS™ = Potentially transformative therapy addressing both the unmet efficacy and safety needs in the important, acute neonatology market = Multiple phase 2 clinical trials producing and replicating efficacy while continuing to build safety and tol

  38. Slide 38: Windtree Therapeutics

    Windtree Therap “Striving to deliver Hope for a Lifetime!” GS winvtREE ue

Windtree Therapeutics — Investor Presentation (January 2018) on 6ix